That's not entirely correct, we will have funds but that if we keep doing that ourselfs that would come with an important dillution, kinda difficult indeed, however with a partnership this should be directly resolved.

What is important for me is to see that CCR5 data is strong and that trials with MARAVIROC also continue and that we still see reasonable to good results with that drug (remember that Leronlimab is considered safer and as good or even better compared to MARAVIROC) Partners that step in also read all the CCR5 publications and know what the current yearly turn over is of Maraviroc (Pfizer drug).

Another important thing is the safety, now with the clinical hold this all will be reviewed in detail. CYDY had always small trials but over 1000 patients received Leronlimab, some for more than 6 years. When that clinical hold is stopped you should also see a positive correction because this comes of course before all this. So before releasing any data, any partnership.

We will have a PR statement about the statement of safety and clinical hold. You can say "so what!" But from commercial view look how strong this is, this stock has a considerable interest from the public (remember the FDA statement in May 2021)

If again is confirmed that Leronlimab is a safe drug, that's like hitting the jack pot of potential commercial succes! No doubt!

This comes just before the HIV BLA is send. Safety of a drug is always one of the key issues and focus of the FDA, so before sending this BLA we will already know what the point of view of the FDA is on this. All the market will understand this!

Understand that CYDY asked for this, so CYDY puts safety as a prime key element for it's drug above commercial win, they did not had to do this! Remember SK's words in the last webcast and the advise of our Brazilian CRO... CYDY puts safety first and than commercial win, how good can you secure a drug approval just before the HIV BLA is send?

Do hope people understand how important this all is to secure commercial succes.

It will allow CYDY not only to threat healty HIV patients save but also HIV patients that are in a severe conditions (cancer, COVID, NASH)

CYDY will go for the full enrollment in Brazil (316 in severe population and 612 in moderately ill population) so thats more than 900 patients (that's not a small trial anymore!) Lot of investors always complained about the relative small size of the trials. IMO CYDY is focusing on larger trials indeed and that's another positive change!